Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1987 May 1;136(9):952–956.

Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.

C R Scriver, D Gregory, M Bernstein, C L Clow, T Weisdorf, G E Dougherty, C Auray-Blais, R Giguère, B Lemieux, C Laberge
PMCID: PMC1491952  PMID: 3105859

Abstract

Neuroblastoma is the most common fatal solid tumour of childhood. Studies in Japan suggest that screening urine at 6 months for tumour-derived metabolites greatly improves early case finding and prognosis. The incidence rate of neuroblastoma in Quebec is at least 1 per 10,330 live births, higher than that of all other diseases responding to early treatment except congenital hypothyroidism screened for in the Quebec Network of Genetic Medicine. The feasibility of chemical screening of urine for elevated levels of homovanillic acid and vanillylmandelic acid in Quebec was assessed. The cost-effectiveness of screening 100,000 infants per year would be high (cost-benefit ratio 2.4), with a net saving of about $280,000 and eight lives per year. The estimated cost of adding neuroblastoma screening to the existing urine metabolite screening program is $70,700. The apparent sensitivity of the proposed test is 0.859 and the rate of false-positive results about 0.1%, both acceptable values. The attitude of potential participants toward the present urine screening program and the addition of a "tumour test" was positive. The results indicate that a pilot study of neuroblastoma screening in Quebec could be undertaken.

Full text

PDF
952

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Evans A. E., D'Angio G. J., Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer. 1971 Feb;27(2):374–378. doi: 10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  2. Klebanoff M. A. Mass screening of neuroblastoma. Am J Dis Child. 1983 Mar;137(3):304–304. doi: 10.1001/archpedi.1983.02140290084029. [DOI] [PubMed] [Google Scholar]
  3. Ostrowsky J. T., Lippman A., Scriver C. R. Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health. 1985 Jul;75(7):732–736. doi: 10.2105/ajph.75.7.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Sawada T., Hirayama M., Nakata T., Takeda T., Takasugi N., Mori T., Maeda K., Koide R., Hanawa Y., Tsunoda A. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet. 1984 Aug 4;2(8397):271–273. doi: 10.1016/s0140-6736(84)90311-8. [DOI] [PubMed] [Google Scholar]
  5. Sawada T., Kidowaki T., Sakamoto I., Hashida T., Matsumura T., Nakagawa M., Kusunoki T. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer. 1984 Jun 15;53(12):2731–2735. doi: 10.1002/1097-0142(19840615)53:12<2731::aid-cncr2820531232>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  6. Sawada T., Kidowaki T., Sugimoto T., Kusunoki T. Incidence of neuroblastoma in infancy in Japan. Med Pediatr Oncol. 1984;12(2):101–103. doi: 10.1002/mpo.2950120208. [DOI] [PubMed] [Google Scholar]
  7. Sawada T., Todo S., Fujita K., Iino S., Imashuku S., Kusunoki T. Mass screening of neuroblastoma in infancy. Am J Dis Child. 1982 Aug;136(8):710–712. doi: 10.1001/archpedi.1982.03970440054015. [DOI] [PubMed] [Google Scholar]
  8. Scriver C. R., Laberge C., Clow C. L., Fraser F. C. Genetics and Medicine: an evolving relationship. Science. 1978 May 26;200(4344):946–952. doi: 10.1126/science.644337. [DOI] [PubMed] [Google Scholar]
  9. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  10. Tuchman M., Crippin P. J., Krivit W. Capillary gas-chromatographic determination of urinary homovanillic acid and vanillylmandelic acid. Clin Chem. 1983 May;29(5):828–831. [PubMed] [Google Scholar]
  11. Tuchman M., Morris C. L., Ramnaraine M. L., Bowers L. D., Krivit W. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections. Pediatrics. 1985 Feb;75(2):324–328. [PubMed] [Google Scholar]
  12. Tuchman M., Ramnaraine M. L., Woods W. G., Krivit W. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics. 1987 Feb;79(2):203–205. [PubMed] [Google Scholar]
  13. Young J. L., Jr, Miller R. W. Incidence of malignant tumors in U. S. children. J Pediatr. 1975 Feb;86(2):254–258. doi: 10.1016/s0022-3476(75)80484-7. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES